Literature DB >> 3108669

HLA-DQ is epistatic to HLA-DR in controlling the immune response to schistosomal antigen in humans.

K Hirayama, S Matsushita, I Kikuchi, M Iuchi, N Ohta, T Sasazuki.   

Abstract

Antigens that produce an antibody response in some members of a species may fail to do so in others. The response to an antigen is controlled by a gene termed the immune response (Ir) gene, which is transmitted as a single dominant trait. We have provided evidence for similar immune suppression (Is) genes which control non-responsiveness through the antigen specific suppressor T cell. The non-responsiveness is also dominantly inherited and the Is genes are linked to the histocompatibility (HLA) antigen system. Here we report that the HLA-DR2 molecule from a non-responder haplotype (HLA-Dw12-DR2-DQwl) is required for the proliferative T cell response to schistosoma japonicum (Sj) antigen, as a restriction element, indicating that the HLA-DR2 is the product of the Ir gene, and that the HLA-DQwl molecule of the non-responder haplotype is important in the antigen-specific suppression of the response to this antigen, suggesting that it is the product of the Is gene. We therefore conclude that the HLA-DR and DQ molecules, which are controlled by the distinct genes in the MHC multigene family, regulate immune response and immune suppression and that the gene for HLA-DQ is epistatic to that for HLA-DR in controlling the immune response to schistosomal antigen in humans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108669     DOI: 10.1038/327426a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

1.  Segregation analysis of IgE responses to Cryptomeria japonica pollen antigen in vivo.

Authors:  K Honda; S Matsushita; N Yasuda; T Juji; T Sasazuki; T Uemura
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

Review 2.  Genetic analysis of susceptibility to type 1 diabetes.

Authors:  J A Todd
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Allele-specific expression of the cytoplasmic exon of HLA-DQB1 gene.

Authors:  S Senju; A Kimura; M Yasunami; N Kamikawaji; H Yoshizumi; Y Nishimura; T Sasazuki
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

4.  Modulation of the HLA class II antigen at a molecular level by maternal serum among cord blood cells and unrelated lymphocytes.

Authors:  Y E Vanderbeeken; J Duchateau; H Colle; M Gregoire; P Desseilles; A Lucas
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

5.  The cellular basis for lack of antibody response to hepatitis B vaccine in humans.

Authors:  E Egea; A Iglesias; M Salazar; C Morimoto; M S Kruskall; Z Awdeh; S F Schlossman; C A Alper; E J Yunis
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

Review 6.  The importance of the back-signal from T cells into antigen-presenting cells in determining susceptibility to parasites.

Authors:  B Müller; A Mitchison
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-09-29       Impact factor: 6.237

Review 7.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

Review 8.  Premises for immune interventional therapy in rheumatoid arthritis.

Authors:  I R Mackay; M J Rowley
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

9.  A high percentage of HLA-DQ+ and HLA-DR+ mononuclear cells is associated with a low incidence of acute graft-versus-host disease after allogeneic bone marrow transplantation (BMT) in children.

Authors:  L Garin; D Rigal; S el Marsafy; J Bernaud; N Philippe; G Souillet
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

10.  Antibody reactivity to an Epstein-Barr virus BERF4-encoded epitope occurring also in Asp-57 region of HLA-DQ8 beta chain. Childhood Diabetes in Finland Study Group.

Authors:  P Parkkonen; H Hyöty; J Ilonen; H Reijonen; S Ylä-Herttuala; P Leinikki
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.